Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xanomeline and Trospium in Healthy Volunteers
NCT02831231Phase 1Completed
- Sponsor
- Karuna Therapeutics
- Start
- Sep 2016
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in schizophrenia comparing Xanomeline + Placebo with Xanomeline + Trospium (2 arms). Primary endpoint: Mean weekly maximum composite Visual Analogue Scale (VAS) score at 7 days. Started Sep 2016; status: completed.
02
Drugs
xanomelinetrospium
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02831231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02831231.